Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography.
The imidazoacridinone C1311 has shown anti-tumour activity both in vitro and in vivo, prompting its acceptance for Phase I clinical trials. A high-performance liquid chromatography method using fluorescence detection has been developed for the analysis of C1311 in mouse and human plasma and mouse tissue samples. This method is selective, sensitive (limit of detection of 1 ng ml-1) and reproducible, with recoveries of > 90%, C1311 was stable over 8 h, at 25 degrees C, in plasma, tumour homogenate, saline and a range of buffers (pH 3.0-8.0). The compound was highly protein bound (> 90%) in plasma which may have important consequences in the pharmacokinetics of the drug.
Calabrese
C R
CR
Clinical Oncology Unit, University of Bradford, West Yorkshire, UK.
Loadman
P M
PM
D000609:Aminoacridines / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000737:chemistry; D011485:Protein Binding; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence
D000609:Aminoacridines; D000970:Antineoplastic Agents; D001798:Blood Proteins; C098965:C 1311